In the current study, PTs of anaemia, thrombocytopenia, nausea, vomiting, constipation, fatigue, blood creatinine increase, ALT/AST increase, and blood cholesterol increase were detected, which were common AEs listed in the label for rucaparib. Here, GPT is linked to anemia (phenotype).